SARS-CoV-2 Mpro inhibitor ensitrelvir: asymmetrical cross-resistance with nirmatrelvir and emerging resistance hotspots

SARS-CoV-2 main protease (Mpro) inhibitors are the first-line COVID-19 treatment. Nirmatrelvir is used worldwide, while ensitrelvir, licensed in Japan and Singapore, has received FDA fast-track designation. To facilitate population monitoring for viral resistance and guide next-generation inhibitor...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Yuyong Zhou, Karen A. Gammeltoft, Helena D. Tjørnelund-Sjursen, Line A. Ryberg, Anna Offersgaard, Anna Czarnota, Zhe Duan, Long V. Pham, Ulrik Fahnøe, Günther H.J. Peters, Santseharay Ramirez, Jens Bukh, Judith M. Gottwein
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Taylor & Francis Group 2025-12-01
Schriftenreihe:	Emerging Microbes and Infections
Schlagworte:	Antiviral resistance SARS-CoV-2 protease inhibitor ensitrelvir nirmatrelvir
Online-Zugang:	https://www.tandfonline.com/doi/10.1080/22221751.2025.2552716
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!